Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.36 |
| ▸ | HRAS | P01112 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237661 | 1.00 | EPHX2 (0.45) | EPHX2NPC1RAB9AP2RX7FAAH | |
| SCHEMBL4864498 | 0.84 | EPHX2 (0.40) | EPHX2NPC1RAB9ACNR2CNR1 | |
| SCHEMBL4864488 | 0.84 | EPHX2 (0.40) | EPHX2NPC1RAB9ACNR2CNR1 | |
| SCHEMBL4862689 | 0.83 | SMN1; SMN2 (0.48) | NPC1RAB9AALDH1A1HTR2C | |
| SCHEMBL4866262 | 0.80 | EPHX2 (0.40) | EPHX2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4866936 | 0.79 | NPC1 (0.44) | EPHX2NPC1RAB9AALDH1A1HRAS | |
| SCHEMBL4870545 | 0.78 | NPC1 (0.41) | EPHX2NPC1RAB9AALDH1A1HRAS | |
| SCHEMBL4866845 | 0.78 | NPC1 (0.43) | EPHX2NPC1RAB9AALDH1A1HRAS | |
| SCHEMBL4532055 | 0.78 | NPC1 (0.43) | EPHX2NPC1RAB9AALDH1A1HRAS | |
| SCHEMBL4870442 | 0.77 | EPHX2 (0.39) | EPHX2NPC1RAB9AALDH1A1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | EPHX2 3740/4885NPC1 1328/4885RAB9A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.